Format

Send to

Choose Destination
Cancer. 2015 Jul 1;121(13):2193-7. doi: 10.1002/cncr.29363. Epub 2015 Mar 30.

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).

Author information

1
Arizona Cancer Center, University of Arizona, Tucson, Arizona.
2
Virginia G. Piper Cancer Center, Scottsdale Healthcare, Scottsdale, Arizona.
3
Southwest Oncology Group Statistical Center, Seattle, Washington.
4
British Columbia Cancer Agency, Vancouver Centre, Vancouver, Canada.
5
USC Norris Comprehensive Cancer Center, Los Angeles, California.
6
University of Kansas Cancer Center, Westwood, Kansas.
7
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California.
8
James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York.
9
Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Abstract

BACKGROUND:

The AKT inhibitor MK-2206 at a dose of 60 mg every other day was evaluated in gastric/gastroesophageal junction cancers.

METHODS:

Patients who had progressed after first-line treatment were eligible. Pertinent eligibility criteria included adequate organ function, a fasting serum glucose level ≤ 150 mg/dL, and less than grade 2 malabsorption or chronic diarrhea. MK-2206 was given orally (60 evaluable patients required). The primary endpoint was overall survival, and a median survival of 6.5 months (power, 89%; significance level, 0.07) was considered encouraging for further investigation.

RESULTS:

Seventy patients were included in the final analyses. The median age was 59.8 years (range, 30.4-86.7 years); 70% were male, 89% were white, and 7% were Asian. There were 2 deaths possibly related to the study drug (cardiac arrest and respiratory failure). Grade 4 adverse events included hyperglycemia, anemia, and lung infection (1 each). Grade 3 adverse events occurred in < 5% of patients except for fatigue (6%). Other adverse events (all grades) included anemia (17%), anorexia (30%), diarrhea (26%), fatigue (50%), hyperglycemia (30%), nausea (40%), vomiting (22%), dry skin (19%), maculopapular rash (30%), and acneiform rash (13%). The response rate was 1%, the median progression-free survival was 1.8 months (95% confidence interval, 1.7-1.8 months), and the median overall survival was 5.1 months (95% confidence interval, 3.7-9.4 months)

CONCLUSIONS:

MK-2206 as second-line therapy was well tolerated by an unselected group of patients with gastric/gastroesophageal junction cancers, but it did not have sufficient activity (response rate, 1%; overall survival, 5.1 months) to warrant further testing in this population.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01260701.

KEYWORDS:

AKT inhibitor; MK-2206; gastric cancer; gastroesophageal junction; phase 2 study

PMID:
25827820
PMCID:
PMC4589423
DOI:
10.1002/cncr.29363
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Secondary source ID, Grant support

Publication types

MeSH terms

Substances

Secondary source ID

Grant support

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center